

ASX ANNOUNCEMENT

25 February 2020

BI-MONTHLY UPDATE

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”) would like to provide the following summary of key announcements made during the past two months.

This is the first of new bi-monthly updates that the Company will issue towards the end of each two month period in 2020. This is part of the Company’s commitment to increased transparency and better communication with its shareholders. Descriptions of each relevant announcement, and it’s lodgement date, are listed below for your reference:


- **20 January 2020:** SaaS company overview as presented to shareholders on Friday 17 January 2020,
- **31 January 2020:** Appointment of world class team,
- **4 February 2020:** Recording of investor presentation on Friday 17 January 2020 – audio recording uploaded to the Company’s website and available as an audio file,
- **12 February 2020:** appointment of Thomas Duthy as a director of the Company.

Note that as part of it’s renewed focus on running an efficient operation, whilst still increasing shareholder communication, the Company is undertaking a concerted effort to rely on electronic communication as much as possible. To this end all shareholders that have not yet provided an email address to the Company are requested to do so by contacting the Company’s registry, Computershare Australia. This will result in significant cost savings.

In the meantime shareholders and potential investors alike are encouraged to read and listen to the above four announcements attached. They give an excellent picture of the Company and where it is heading. As far as the markets the Company is targeting it is worth noting that there are about 350m asthma sufferers worldwide. In Australia, 11.2% (or 2.7m) of the population have asthma according to the Australian Bureau of statistics as of 2017/18. This puts about 400,000 Australians with moderate asthma and around 200,000 with severe asthma.

While asthma prevalence does vary between geographies these same figures can be proportionally applied to the United States and Europe which are both target markets of Respiri following launch in Australia in 2020.

If any shareholders have additional questions, please send them through to info@respiri.co. The company will address these in future company updates to keep all of its shareholders informed.



Alastair Beard
Company Secretary
---End---

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi's current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.